Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127843 | 1.00 | SIGMAR1 (0.63) | SIGMAR1BCHEATMGAAPOLB | |
| SCHEMBL8908664 | 0.87 | SIGMAR1 (0.58) | SIGMAR1BCHEATMGAAPOLB | |
| SCHEMBL1005593 | 0.84 | SIGMAR1 (0.68) | SIGMAR1BCHEATMGAAPOLB | |
| SCHEMBL1189292 | 0.84 | SIGMAR1 (0.68) | SIGMAR1BCHEATMGAAPOLB | |
| SCHEMBL1005591 | 0.84 | SIGMAR1 (0.68) | SIGMAR1BCHEATMGAAPOLB | |
| SCHEMBL10451642 | 0.82 | BCHE (0.71) | SIGMAR1BCHEATMGAAOPRK1 | |
| SCHEMBL172531 | 0.82 | SIGMAR1 (0.66) | SIGMAR1BCHEATMGAAPOLB | |
| SCHEMBL11096038 | 0.82 | BCHE (0.71) | SIGMAR1BCHEATMGAAOPRK1 | |
| SCHEMBL203279 | 0.82 | L3MBTL1 (0.58) | SIGMAR1BCHEATMGAAPOLB | |
| Hydrochloric Acid SCHEMBL27619587 | 0.81 | SIGMAR1 (0.63) | SIGMAR1BCHEATMGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573089-A2 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240199584-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-20 | — | — | US | disclosed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-8853224-B2 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2014-10-07 | — | — | US | disclosed |
| CN-101528749-B | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | IND RES LTD | 2013-07-31 | — | — | CN | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | BIOCRYST PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| EP-2323974-A1 | METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO | Ube Industries, Ltd. (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010114179-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | WO | disclosed |
| US-20100152463-A1 | Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto | IM&T RESEARCH, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010022001-A1 | METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO | IM&T RESEARCH, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2008030119-A9 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-09-24 | — | — | WO | disclosed |
| CN-101528749-A | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | IND RES LTD (NZ) | 2009-09-09 | — | — | CN | disclosed |
| EP-2057165-A1 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008077799-A2 | COMPOUNDS AND METHODS FOR AMINO-ALKYLENEDIOL SYNTHESIS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008030119-A1 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152463-A1 | Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto | PFAS, AGPS, FDPS | SIGMAR1 2031/4885BCHE 1190/4885ATM 2413/4885 |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | PSEN1, MAPT, PSEN2 | SIGMAR1 1613/4885BCHE 586/4885ATM 390/4885 |
| US-20240199584-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | SIGMAR1 4517/4885BCHE 4645/4885ATM 365/4885 |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | PNP, TYMP, NTPCR | SIGMAR1 3759/4885BCHE 130/4885ATM 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.